Medicines Optimisation & Pharmacy Procurement Primary Care Sub-group
The Primary Care Medicines Optimisation & Pharmacy Procurement Sub-group is a strategic London-wide group whose members are clinicians and commissioners from the CCGs within London, the NHS London Procurement Partnership, and Specialist Pharmacy Services. They are working together to ensure that there is a consistent approach to the work of the medicines optimisation and pharmacy procurement QIPP workstream across London.
The overall aims of the sub-group are to promote the cost-effective and equitable provision of medicines, and to facilitate consistency of approach, collaboration and sharing of good practice in prescribing and medicines use and procurement within London. It is an opportunity to engage primary care colleagues and other specialists at a central point, leading to mutually agreed decisions and practice.
The benefits to patients and the London organisations of having an effective and integrated approach to QIPP and medicines use and procurement include:
- Promoting co-operation and consistency of approach in the medicines use and procurement QIPP workstream.
- Preventing duplication of professional and managerial effort by ensuring joint and collaborative working
- Enabling key stakeholders, working in the NHS locally, to influence the prioritisation, improvement and development of healthcare delivery.
- Co-ordinating the safe and cost effective use of medicines across London to improve outcomes for patients.
- Agree clinical priorities and KPIs for each financial year. Provide cluster and CCG level reports on agreed priorities.
- Continue with the maintenance and development of the primary care QIPP dashboard.
- Identify and disseminate good practice across London and encourage collaboration and sharing where appropriate.
- Support clusters to engage with CCGs.
- Engage with secondary care colleagues to raise awareness of QIPP priorities for primary care medicines.
- Engage with community pharmacists to raise awareness of QIPP priorities for primary care medicines.
- To consider clinical initiatives that can be taken forward across the primary and secondary care interface and how best to progress these.
- To peer review cluster prescribing data against key agreed priorities and identify the support tools required to help improve performance locally.
- Ensure patient safety is incorporated as a specific issue in all decisions and recommendations made by the group, including the safety aspects of the way medicines are used in practice.
- Encourage, support and monitor how the advice, once agreed, is implemented and endorsed by relevant organisations, for example, through an implementation and monitoring plan.
- Work in conjunction with the clinical networks in London to ensure that consistent messages are being sent out across London.